{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:24:38Z","timestamp":1793813078788,"version":"4.6.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008866","name":"Changhai Hospital of Shanghai","doi-asserted-by":"publisher","award":["2023PY08"],"award-info":[{"award-number":["2023PY08"]}],"id":[{"id":"10.13039\/501100008866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700548"],"award-info":[{"award-number":["81700548"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008050","name":"University of Shanghai for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ekir.2026.106527","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:07:45Z","timestamp":1775030865000},"page":"106527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Telitacicept in Posttransplant Recurrent IgA Nephropathy"],"prefix":"10.1016","volume":"11","author":[{"given":"Mingxing","family":"Sui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106527_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106527_bib2","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40620-024-02149-6","article-title":"Post-transplant IgA nephropathy: a rapidly evolving field of kidney transplant medicine","volume":"38","author":"Kanbay","year":"2024","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2026.106527_bib3","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1097\/TP.0000000000001093","article-title":"Recurrent IgA nephropathy after kidney transplantation","volume":"100","author":"Wyld","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106527_bib4","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3389\/fimmu.2019.01332","article-title":"Immunoglobulin A nephropathy. Recurrence after renal transplantation","volume":"10","author":"Moroni","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.106527_bib5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1440-1827.2004.01751.x","article-title":"Glomerular crescents are responsible for chronic graft dysfunction in post-transplant IgA nephropathy","volume":"54","author":"Jeong","year":"2004","journal-title":"Pathol Int"},{"key":"10.1016\/j.ekir.2026.106527_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf324","article-title":"The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective","volume":"18","author":"Stamellou","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106527_bib7","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/j.1600-6143.2011.03667.x","article-title":"Steroids and recurrent IgA nephropathy after kidney transplantation","volume":"11","author":"Clayton","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106527_bib8","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106527_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106527_bib10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fmed.2020.00092","article-title":"The role of immune modulation in pathogenesis of IgA nephropathy","volume":"7","author":"Chang","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2026.106527_bib11","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1093\/ndt\/gfaf049","article-title":"Real world data on dual BLyS\/APRIL inhibition with telitacicept for lupus nephritis","volume":"40","author":"Jin","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106527_bib12","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ekir.2024.11.1363","article-title":"Efficacy and safety of telitacicept as an add-on therapy for refractory immunoglobulin A nephropathy or immunoglobulin A vasculitis nephropathy in children","volume":"10","author":"Liu","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106527_bib13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized Phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106527_bib14","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/ndt\/gfad146","article-title":"IgA nephropathy in adults-treatment standard","volume":"38","author":"Gleeson","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106527_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae285","article-title":"Efficacy and safety of telitacicept, a BLyS\/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study","volume":"17","author":"Wang","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106527_bib16","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/0016-5085(88)90252-1","article-title":"Receptor-mediated binding and uptake of immunoglobulin A by human liver","volume":"94","author":"Tomana","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ekir.2026.106527_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1681\/ASN.V112241","article-title":"Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells","volume":"11","author":"Leung","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106527_bib18","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/ndt\/gfs445","article-title":"Deposition of IgA in primary IgA nephropathy: it takes at least four to tango","volume":"28","author":"Daha","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106527_bib19","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/ki.2015.158","article-title":"Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes","volume":"88","author":"Berthelot","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106527_bib20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.kint.2021.09.023","article-title":"Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy","volume":"101","author":"Cambier","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106527_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1084\/jem.194.4.417","article-title":"Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy","volume":"194","author":"Moura","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.ekir.2026.106527_bib22","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1038\/s41467-025-60819-w","article-title":"Lysosome-mediated aggregation of galactose-deficient IgA1 with transferrin receptor 1 links to IgA nephropathy","volume":"16","author":"Si","year":"2025","journal-title":"Nat Commun"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2026.106527_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000530341","article-title":"Current status and perspectives on recurrent IgA nephropathy after kidney transplantation","volume":"147","author":"Kawabe","year":"2023","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2026.106527_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.926517","article-title":"Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: a comprehensive review","volume":"13","author":"Liao","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.106527_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12882-017-0467-z","article-title":"Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis","volume":"18","author":"Song","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2026.106527_bib26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.kint.2023.02.012","article-title":"Targeted-release budesonide in recurrent IgA nephropathy after kidney transplantation","volume":"103","author":"Gandolfini","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106527_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.71474","article-title":"Treatment of recurrent IgA nephropathy after kidney transplantation: case report and comprehensive literature review","volume":"13","author":"Matarneh","year":"2025","journal-title":"Clin Case Rep"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:24:25Z","timestamp":1780478665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926027592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2468024926027592"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106527","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Telitacicept in Posttransplant Recurrent IgA Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"106527"}}